Moreover, several studies have shown over-expression of SOX2 in various cancers including glioblastoma [9], non-small cell lung cancer [10], [11], prostate cancer [12] and hepatocellular carcinomas [13] supporting SOX2 as a relevant oncogene in these malignancies. The gene discussed is SOX2; the disease is prostate carcinoma.